BioIntellisense, Inc. announced that it has received $45 million in its series B a round of funding led by new investor Chimera Investments LLC. on July 28, 2021. The transaction included participation from new investors 7wire Ventures, Pendrell Corporation, Fresenius Medical Care North America Holdings Limited Partnership, Mary Tolan, James Murren, Koninklijke Philips N.V. returning investors Tripletree Holdings, Llc, CU Healthcare Innovation Fund, L.P. a fund managed by University of Colorado School of Medicine, Endowment Arm and University Of Colorado Hospital Authority.

The transaction was oversubscribed.